Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 2 days agoScore90
Body
HERIZON-GEA-01 at #ESMO26:
Zanidatamab + chemotherapy improved PFS and OS versus trastuzumab-based therapy in 1L HER2+ advanced GEA. The triplet regimen with tislelizumab achieved a median OS of 27 months and a 3-year OS rate of 40%.
@OncoAlert #HER2Positive
872 views · 18 likes · 5 reposts · 1 reply
Conference abstracts
LBA79matched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01
https://esmocongress.esmo.orgReplies in this thread
- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@OncoAlert @myESMO A meaningful advance in 1L treatment, with the incremental benefit of immunotherapy and long-term tolerability remaining key considerations.
Source: Aya Mohamed | MSc, MD 🎗 · x.com